HC Wainwright Reaffirms “Buy” Rating for XOMA (NASDAQ:XOMA)

HC Wainwright reissued their buy rating on shares of XOMA (NASDAQ:XOMA) in a research report sent to investors on Tuesday, Benzinga reports. They currently have a $74.00 price target on the biotechnology company’s stock.

Several other equities analysts also recently commented on XOMA. SVB Leerink started coverage on shares of XOMA in a report on Monday, April 29th. They issued an outperform rating and a $40.00 target price on the stock. Leerink Partnrs reissued an outperform rating on shares of XOMA in a report on Monday, April 29th.

XOMA Price Performance

Shares of NASDAQ:XOMA opened at $27.00 on Tuesday. The company has a debt-to-equity ratio of 1.39, a current ratio of 9.45 and a quick ratio of 9.45. XOMA has a 1-year low of $13.48 and a 1-year high of $27.36. The company has a market capitalization of $314.25 million, a P/E ratio of -6.89 and a beta of 0.93. The firm’s 50 day simple moving average is $24.83 and its two-hundred day simple moving average is $23.65.

XOMA (NASDAQ:XOMA) last issued its quarterly earnings results on Thursday, May 9th. The biotechnology company reported ($0.86) earnings per share for the quarter, missing the consensus estimate of ($0.71) by ($0.15). XOMA had a negative net margin of 705.23% and a negative return on equity of 26.00%. The firm had revenue of $1.49 million for the quarter, compared to analysts’ expectations of $0.96 million. Research analysts expect that XOMA will post -1.76 EPS for the current fiscal year.

Institutional Investors Weigh In On XOMA

A hedge fund recently bought a new stake in XOMA stock. Price T Rowe Associates Inc. MD purchased a new stake in shares of XOMA Co. (NASDAQ:XOMA) during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 8,778 shares of the biotechnology company’s stock, valued at approximately $212,000. Price T Rowe Associates Inc. MD owned approximately 0.08% of XOMA as of its most recent SEC filing. 95.92% of the stock is owned by institutional investors.

About XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.